Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien Enters Biologic Tissue Implant Market Via $80 Mil. TSL Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Covidien gains the Permacol biologic tissue repair implant for hernias and other applications through its $80 million purchase of Tissue Science Laboratories, announced March 12

You may also be interested in...



Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy

Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million

Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy

Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million

Covidien Device Sales Grow 3% In Q1; Respiratory Biz Still Struggling

Covidien's medical device revenues grew 3% to $1.6 billion in the firm's fiscal first quarter, with stronger contributions from its endomechanical and energy businesses offset by continuing weakness in sales of respiratory products

Related Content

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel